Beam Therapeutics (BEAM) Net Equity Issued and Repurchased (2021 - 2023)

Beam Therapeutics (BEAM) has 3 years of Net Equity Issued and Repurchased data on file, last reported at $34.9 million in Q3 2023.

• On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $34.9 million in Q3 2023; TTM through Dec 2023 was $236.6 million, a 118.52% increase from a year earlier, with the FY2023 full-year figure at $236.6 million, up 118.52% from the prior year.
• Net Equity Issued and Repurchased for Q3 2023 stood at $34.9 million, down from $107.6 million in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for BEAM reached as high as $318.9 million in Q3 2021 and fell as low as $20.2 million in Q4 2021.
• Historically, Net Equity Issued and Repurchased has averaged $110.2 million across 3 years, with a median of $74.0 million in 2022.
• Across the five-year window, Net Equity Issued and Repurchased sank 85.87% in 2022 and surged 381.36% in 2023, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at $20.2 million in 2021, then soared by 57.54% to $31.9 million in 2022, then rose by 9.57% to $34.9 million in 2023.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $34.9 million in Q3 2023, $107.6 million in Q2 2023, and $94.0 million in Q1 2023.